Analyst: This Drug Stock Could Double

H.C. Wainwright started coverage of UROV shares with a "buy" rating

Mar 11, 2019 at 1:50 PM
facebook twitter linkedin

The shares of Urovant Sciences Ltd (NASDAQ:UROV) are up 1.9% to trade at $13.30 today, after analysts at H.C. Wainwright launched coverage with a "buy" rating. What's more, the brokerage firm set a Street-high price target of $28 for UROV, representing more than double the equity's current price -- and twice its initial public offering (IPO) price of $14. The analyst waxed optimistic on Urovant Sciences' lead product, vibegron, which treats overactive bladder -- a condition that is increasing in step with the aging U.S. population.

UROV stock went public in late September, and peaked at $14.32 on Oct. 4. The equity subsequently plummeted to a record low of $4.05 by Dec. 21, before erasing almost all of that deficit in 2019. The Wall Street freshman hasn't closed a day above that key $14 IPO price ever, though.

UROV stock chart march 11

Although UROV has been trading just a few months, it's no stranger to upbeat analyst attention. All four brokerage firms following the shares deem it worthy of a "buy" or better rating, and the consensus 12-month price target of $24 represents expected upside of 80.5% to the security's current perch.

In conclusion, traders should keep an eye on Urovant stock's dance around the key $14 level, as a close above its IPO price could mark a psychological hurdle for investors. Meanwhile, it should be noted that UROV's lock-up period expires on March 25.


If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Master Portfolio Trial


Special Offers from Schaeffer's Trading Partners